The Golgi complex has a central role in the intracellular sorting of secretory proteins 1, 2 . Anterograde transport through the Golgi has been explained by the movement of Golgi cisternae, known as cisternal maturation [3] [4] [5] . Because this explanation is now appreciated to be incomplete 6 , interest has developed in understanding tubules that connect the Golgi cisternae [7] [8] [9] . Here we show that the coat protein I (COPI) complex sorts anterograde cargoes into these tubules in human cells. Moreover, the small GTPase CDC42 regulates bidirectional Golgi transport by targeting the dual functions of COPI in cargo sorting and carrier formation. CDC42 also directly imparts membrane curvature to promote COPI tubule formation. Our findings further reveal that COPI tubular transport complements cisternal maturation in explaining how anterograde Golgi transport is achieved, and that bidirectional COPI transport is modulated by environmental cues through CDC42.
In addition to its known role in generating vesicles 10 , we recently discovered that COPI also generates tubules that connect the Golgi stacks 9 . However, whether these tubules act passively or actively in cargo transport has been unclear. Active transport involves coat proteins binding to cargoes. Thus, we initially examined whether COPI binds to a temperature-sensitive form of the vesicular stomatitis virus G protein (hereafter referred as VSVG), which has been widely used to track anterograde Golgi transport [6] [7] [8] [9] . We found that coatomer, the core component of the COPI complex 10 , binds directly to the cytoplasmic tail of VSVG ( Fig. 1a and Extended Data Fig. 1a ). Further defining this binding, we found that coatomer binds to the membrane-proximal region of the VSVG tail ( Fig. 1b and Extended Data Fig. 1b ), and then identified residues within this region crucial for binding by coatomer ( Fig. 1c and Extended Data Fig. 1a ).
Coatomer has been shown previously to promote the retrograde transport of cargoes, such as WBP1 (ref. 11 ) and the KDEL receptor 12 , which involves binding to their carboxy terminus that contains dilysine residues. By contrast, the basic residues in VSVG recognized by coatomer are situated away from this end (see Extended Data Fig.  1a ), suggesting a new mode of cargo recognition by coatomer. As confirmation, we performed competition studies, and verified that a peptide derived from WBP1 (containing the retrograde di-lysine motif) cannot compete with the VSVG tail for binding to coatomer (Fig. 1d ). We also used fluorescence lifetime imaging microscopy (FLIM) to confirm that coatomer interacts with VSVG at the Golgi, and the interaction requires crucial basic residues in VSVG ( Fig. 1e and Extended Data Fig. 1c ). Subsequently, we found that mutation of these basic residues delayed the transport of VSVG from the endoplasmic reticulum (ER) to the trans-Golgi ( Fig. 1f and Extended Data Fig. 1d ), but not from the ER to the cis-Golgi (Extended Data Fig. 1e ). Thus, coatomer promotes the intra-Golgi transport of VSVG through cargo binding.
We next examined another anterograde cargo, the endogenous lowdensity lipoprotein receptor (LDLR). Coatomer also binds directly to its cytoplasmic tail (Fig 2a) , which is also not affected by the presence of the WBP1 peptide (Fig. 2b) . As the LDLR tail also contains basic residues away from the C terminus (Extended Data Fig. 2a ), we next targeted them for mutagenesis and found that binding to the LDLR tail by coatomer became reduced ( Fig. 2a ). To confirm the functional role of this binding, we swapped the tails of LDLR and VSVG, and then examined the transport of the resulting chimaera (VSVG-LDLR). When crucial basic residues in the LDLR tail were mutated, we observed delayed transport of VSVG-LDLR from the ER to the trans-Golgi ( Fig. 2c and Extended Data Fig. 2b ), but not from the ER to the cis-Golgi (Extended Data Fig. 2c ).
As compared to VSVG, VSVG-LDLR is transported slower from the ER to the cis-Golgi (Extended Data Figs 1e and 2c), and also through the Golgi (Fig 2d and Extended Data Fig. 2d ). Pursuing the latter observation, we found that coatomer binds more efficiently to the VSVG tail than the LDLR tail, both in vitro ( Fig. 2e ) and in cells ( Fig. 2f and Extended Data Fig. 3a ). Moreover, mutating critical basic residues in either cargo tail results in transport rates becoming similar ( Fig. 2d and Extended Data Fig. 2d ). Furthermore, mutating a residue in VSVG that partially reduces its binding by coatomer (His494Ala in Fig. 1c ) moderately reduces VSVG transport through the Golgi (Extended Data Fig. 3b ). Thus, the collective results further confirmed that binding of anterograde cargoes by coatomer promotes their transport through the Golgi.
We then sought to address how the same coat complex can promote opposing directions of Golgi transport while also maintaining specificity in cargo sorting. As a clue, we noted that CDC42 has been found previously to interact with coatomer 13 . Moreover, the CDC42(Phe28Leu) point mutation, which promotes the rapid cycling of its GTPase cycle, enhances VSVG transport 13 . We initially defined more precisely that active CDC42(Phe28Leu) promotes the intra-Golgi segment of VSVG transport ( Fig. 3a and Extended Data Fig.  4a ), with short interfering RNA (siRNA) against CDC42 (Extended Data Fig. 4b ) having the opposite effect (Extended Data Fig. 4c ). By contrast, no effect was seen on transport from the ER to the cis-Golgi (Extended Data Fig. 4d, e ). We then considered that COPI tubular transport at the Golgi requires cytosolic phospholipase A 2a (cPLA 2a ) activity 9 . Targeting this activity using siRNA, we found that CDC42 can no longer promote the anterograde transport of VSVG through the Golgi (Fig. 3b and Extended Data Fig. 5a ). Next, examining retrograde COPI vesicular transport, as tracked through a model cargo (VSVG-KDELR 9, 14, 15 ), we found that active CDC42(Phe28Leu) inhibits this transport ( Fig. 3c and Extended Data Fig. 5b ), whereas CDC42 siRNA enhances this transport (Extended Data Fig. 5c ). Thus, the collective results revealed that CDC42 has opposite effects on the two directions of COPI transport at the Golgi, promoting anterograde tubular transport and inhibiting retrograde vesicular transport.
We then sought to determine how CDC42 exerts these effects. We had previously found that retrograde cargoes are preferentially sorted into COPI vesicles generated through a reconstitution system 9 . However, reconstituted COPI tubules contain both anterograde and retrograde cargoes 9 . Thus, to explore whether CDC42 acts to specify cargo sorting into these tubules, we added CDC42 to the reconstitution system. Remarkably, the level of a retrograde cargo (VSVG-KDELR) in COPI tubules became reduced ( Fig. 3d ), while that of an anterograde cargo (VSVG) was unaffected ( Fig. 3e ). In considering how CDC42 achieves these effects, we noted that CDC42 possesses a di-lysine motif, which competes with retrograde cargoes for binding to coatomer 13 . Pursuing this clue, we found that active CDC42 prevents coatomer from binding to the retrograde cargo (KDELR) tail ( Fig. 3f ), but not coatomer binding to the anterograde cargo (VSVG) tail ( Fig. 3g ). These results were further confirmed by FLIM (Extended Data Fig.  5d , e). We also examined a range of other small GTPases known to act in Golgi transport, and found that none of them affects coatomer binding to either the VSVG tail (Extended Data Fig. 6a ) or the KDELR tail (Extended Data Fig. 6b ). Other Rho small GTPases also did not have an effect (Extended Data Fig. 6a, b) . Thus, the collective results suggested that CDC42 imparts specificity in cargo sorting into COPI tubules by competing with retrograde, but not anterograde, cargoes for binding to coatomer.
Besides cargo sorting, the other major function of coat proteins is the generation of transport carriers. Previously, we found that the addition of cPLA 2a to the COPI reconstitution system diverts vesicle formation to tubule formation 9 . Remarkably, when we replaced cPLA 2a with the active CDC42(Phe28Leu), COPI tubule formation was also promoted (Fig. 4a ), and at the expense of vesicle formation (Fig. 4b ). In considering how CDC42 exerts these effects, we initially ruled out that CDC42 acts through cPLA 2a , as the replacement of wildtype cPLA 2a with the catalytic dead form in the COPI reconstitution system did not prevent active CDC42 from promoting tubule formation (Extended Data Fig. 6c ), and also inhibiting vesicle formation (Extended Data Fig. 6d ). To decipher a different explanation, we noted that protein factors can directly impart membrane curvature, as reflected by their ability to tubulate liposomes 16, 17 . Notably, when we incubated active CDC42(Phe28Leu) with liposomes, tubulation was observed ( Fig. 4c, d ).
To determine how CDC42 exerts this effect, we initially considered that CDC42 is prenylated, which suggests how the GTPase can insert asymmetrically into the membrane bilayer to impart curvature. As confirmation, we found that a non-prenylated form of CDC42 cannot induce liposome tubulation ( Fig. 4c, d ). We then considered that CDC42 undergoes dimerization 18 , which suggested an additional possibility that it can polymerize onto membrane to exert curvature through scaffolding. Performing mutagenesis, we identified three residues at the C terminus of CDC42, anchored by di-arginine residues (Extended Data Fig. 7a ), to be required for dimerization (Extended Data Fig. 7b ). When the di-arginine residues were mutated, we found that active CDC42(Phe28Leu) can no longer tubulate liposomes ( Fig. 4c, d ). As further confirmation, we found that mutating the diarginine residues also prevents CDC42 from promoting tubule formation in the COPI reconstitution system ( Fig. 4e ). Moreover, this mutation prevents CDC42 from promoting the intra-Golgi transport of VSVG ( Fig. 4f and Extended Data Fig. 7c ). We also considered that the di-arginine residues are closely juxtaposed to the di-lysine residues in CDC42 (Extended Data Fig. 7a ). Thus, we assessed whether the di-arginine residues have a role in COPI cargo sorting. However, mutation of the di-arginine residues does not prevent activated CDC42(Phe28Leu) from interacting with coatomer (Extended Data Fig. 7d ). Moreover, this mutation also does not alter the ability of active CDC42(Phe28Leu) to inhibit coatomer binding to the retrograde (KDELR) cargo (Extended Data Fig. 7e ). In comparison, mutating the di-lysine residues in CDC42 affects this cargo binding by coatomer (Extended Data Fig. 7f ). These binding results were also further confirmed in cells through FLIM (Extended Data Fig. 7g ).
We next considered that coatomer has been identified as a target by which CDC42 promotes cellular transformation 13 . Led by this finding, we found that serum induces similar effects on bidirectional Golgi transport as activated CDC42 (Extended Data Fig. 8a, b ). Moreover, epidermal growth factor (EGF) can replace serum in exerting these effects (Extended Data Fig. 8c, d ). By contrast, neither serum (Extended Data Fig. 8e ) nor EGF (Extended Data Fig. 8f ) affects transport from the ER to the cis-Golgi. Mechanistically, serum acts through CDC42, as the enhanced anterograde transport of VSVG (Extended Data Fig. 8a ) and the inhibited retrograde transport of VSVG-KDELR (Extended Data Fig. 8b ) are prevented after CDC42 siRNA. This was also the case for EGF stimulation (Extended Data Fig. 8c, d) .
We then considered that the SRC kinase has also been shown to promote anterograde Golgi transport 19 . Using siRNA targeting the SRC gene, we found that serum can no longer modulate bidirectional Golgi transport (Extended Data Fig. 9a, b ). We also found that pharmacological activation of SRC reproduces the effects of serum (Extended Data Fig. 9c, d ). Moreover, CDC42 siRNA prevents SRC activation from exerting these effects (Extended Data Fig. 9c, d ). Thus, we concluded that a signalling cascade, which involves growth factors activating SRC and then CDC42, modulates bidirectional Golgi transport (Extended Data Fig. 10a ). Notably, as siRNA against cPLA 2a prevents the ability of SRC activation to promote VSVG transport through the Golgi (Extended Data Fig. 10b ), we further concluded that the signalling cascade targets COPI tubular transport in promoting anterograde Golgi transport.
In summary, we have advanced a new understanding of how Golgi transport is achieved and regulated. Our findings also address a continuing controversy about the role of COPI in anterograde Golgi transport. Although this debate has focused on the role of COPI vesicular transport 20 , we provide a reconciling explanation by showing how COPI acts anterograde through tubular transport. Another notable finding is that CDC42 acts not just as a regulator of cellular events, but also as an effector, which in the case of COPI transport involves a direct ability to impart membrane curvature. Our results also shed new insight into how CDC42 targets coatomer for cellular transformation. Whereas CDC42 was previously thought to affect COPI transport in the retrograde direction 13 , our finding that CDC42 modulates bidirectional COPI transport to favour the anterograde direction suggests more readily how transformation is promoted, as the rapid growth and division of tumours is predicted to require enhanced secretion.
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METHODS
Chemicals, lipids, peptides and cells. The SRC family activator (Santa Cruz, SC3052) has been described 22 . GDP and GTP were purchased (Sigma-Aldrich). DOPC (dioleoylphosphatidylcholine), DOPE (dioleoylphosphatidylethanolamine), DOPS (dioleoylphosphatidylserine), phosphatidic acid and cholesterol were also purchased (Avanti Polar Lipid). Peptides encoding the WBP1 tail (wild-type, KKLETFKKTN; mutant, KKLETFSSTN) were synthesized (GenScript). Culturing of HeLa cells has been described 9, 14, 15 .
Antibodies. Mouse anti-b subunit of coatomer, anti-f subunit of coatomer, mouse anti-Myc (9E10), sheep anti-TGN46, rabbit anti-giantin antibodies have been described previously 21 . Rabbit anti-Myc antibody (2278S), rabbit anti-CDC42 antibody (2462S), and mouse anti-b-actin antibody (3700P) were obtained (Cell Signaling). All secondary antibodies were also obtained (Jackson ImmunoResearch Laboratory).
Purified and recombinant proteins. Preparation of coatomer, ARF1, ARFGAP1, BARS, cPLA 2a and Golgi membrane have been described 9, 12, 14 . To generate the prenylated form of human CDC42, pFASTBAC THb (Invitrogen) was used to generate baculovirus using Bac-to-Bac Baculovirus Expression system (Invitrogen). Infected Sf9 cells were resuspended in hypotonic buffer (20 mM sodium borate, pH 10.2, 5 mM MgCl 2 , and protease inhibitor) followed by lysis using dounce homogenizer. Membrane-bound CDC42 was collected by 150,000g centrifugation for 30 min. The pellet was then resuspended with TBS-M (50 mM Tris (pH 7.2), 150 mM NaCl, 5 mM MgCl 2 and protease inhibitor), followed by centrifugation at 150,000g for 30 min. Prenylated CDC42 was solubilized from membranes using TBS-M containing 1% Triton X-100 for 1 h, followed by centrifugation at 9,000g for 20 min. The histidine-tagged CDC42 was then purified from the supernatant fraction using a nickel column. Non-prenylated CDC42 was generated using bacterial expression. The last three amino acids were deleted to mimic the protein sequence of the prenylated form (see Extended Data Fig. 7a ).
Human CDC42 in pET-15b (Novagen) was expressed in bacteria (BL21) with 100 mM of isopropyl-b-D-thiogalactopyranoside (IPTG) induction at 37 uC for 2 h. The His-tagged CDC42 was isolated with a nickel column, and then released with elution buffer (50 mM Tris (pH 7.2), 500 mM NaCl, 5 mM MgCl 2 , 0.1% CHAPS and 250 mM imidazole). Recombinant forms of RAC1, RhoA and RAB1A, RAB2A, RAB6A and RAB33B were generated similarly.
Plasmids. Cytoplasmic domain of cargoes fused to glutathione S-transferase (GST) was generated using in vitro annealing. Paired oligonucleotides were annealed in buffer (30 mM HEPES-KOH, pH 7.4, 150 mM KCl, 2 mM MgCl 2 ) at 90 uC for 1 min followed by cooling down. Annealed duplexes were inserted into pGEX-4T-3 (GE Healthcare). GST-fused cytoplasmic peptides of LDLR were generated using PCR. VSVG-LDLR was generated by fusing the cytoplasmic tail of LDLR to the luminal and transmembrane domains of VSVG-ts045. Mutations were generated using PCR or QuikChange Site-Directed-Mutagenesis (Strategene). VSVG-ts045 and VSVG-ts045-KDELR have been described previously 21 . CDC42(Phe28Leu) mutant, and the di-lysine mutant of CDC42(Phe28Leu) in pFASTBAC THb and PKH3 were gifts from R. A. Cerione. Di-arginine mutant of CDC42 was generated using PCR with paired oligonucleotides. Additional plasmids were obtained and then subcloned into pET-15b to generate recombinant proteins: RAC1 and RhoA (D. Manor), RAB1A, RAB2A and RAB6A (D. Lambright), and RAB33B (M. Fukuda). See Supplementary Information for details on the oligonucleotides used to generate chimaeric constructs and point mutations.
Transfections and siRNA. Transfection of DNA plasmids was performed using FuGene6 (Roche). Transfection of siRNA was carried out using Lipofectamine RNAiMAX (Invitrogen). The siRNA sequence against cPLA 2a (targeting the PLA2G4A gene) has been described previously 9 . The siRNA sequences used to target human CDC42 (59-GATAACTCACCACTGTCCA-39) and human SRC (59-TGTTCGGAGGCTTCAACTCCT-39) were obtained (Dharmacon). Point mutations in CDC42 to render siRNA resistant were generated using oligonucleotides (59-GAAAAGTGGGTGCCTGAGATAACTCATCACTGTCCAAAGAC TCCTTTCTTGCTTGTTGGG-39 and 59-CCCAACAAGCAAGAAAGGAGTC TTTGGACAGTGATGAGTTATCTCAGGCACCCACTTTTC-39).
In vitro binding assays. GST fusions were expressed in bacteria (BL21 cell) with ITPG induction. After lysis in buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mg ml 21 of lysozyme and protease inhibitor), GST peptide was incubated with glutathione Sepharose beads (GE Healthcare). GST fusions on beads were then incubated with purified coatomer (2.5 nM) at 4 uC for 1 h in incubation buffer (25 mM HEPES, pH 7.2, 50 mM KCl, 2.5 mM magnesium acetate and 0.5% NP-40). For competition experiments with peptides, GST fusions on beads were co-incubated with coatomer and peptide at 4 uC for 1 h in incubation buffer. Beads were then rinsed twice with incubation buffer and then analysed by SDS-PAGE followed by immunoblotting or Coomassie staining. For competition experiments with small GTPases, GTPases were loaded with either GTP or GDP and then incubated with cargo (as GST fusions on beads) and coatomer. Quantification was performed by analysing the level of coatomer and normalizing for the level of cargo on beads.
In vivo transport assays. Anterograde transport of VSVG and retrograde transport of VSVG-KDELR have been described previously 9, 21 . In brief, HeLa cells were transfected with VSVG-ts045 and VSVG-ts045-KDELR to track anterograde and retrograde transport, respectively. To track transport from the ER to the Golgi, cells were incubated at 40 uC for 2 h to accumulate a synchronized pool of VSVG at the ER. Cells were then shifted to incubation at 32 uC to allow transport from the ER to proceed. To examine intra-Golgi transport, cells were incubated at 15 uC for 2 h to accumulate a synchronized pool of VSVG at the pre-Golgi region, followed by a shift to 32 uC to allow transport through the Golgi. To study retrograde transport, cells expressing VSVG-ts045-KDELR were incubated at 32 uC for 2 h. Cells were then incubated at 40 uC. This prevents further anterograde transport from the ER, and thereby allowing one round of retrograde transport from the Golgi to the ER to be assessed. In stimulation experiments, cells were starved using DMEM supplemented with 0.1% BSA for 2 h followed by stimulation with serum or a SRC activator phosphopeptide 22 (10 mM) for 1 h. Transport was quantified by measuring (Metamorph) the colocalization of cargoes with organelle markers over time.
FLIM. Interactions were monitored using time-correlated single-photon counting fluorescence lifetime image microscopy analysis (TCSPC-FLIM), which has been described previously 23,24 . In brief, the different forms of VSVG were detected through the Myc tag appended at the C terminus using an anti-Myc antibody. This antibody was then detected with a secondary antibody conjugated to Alexa Fluor 594 (acceptor fluorophore). Coatomer was detected with the anti-coatomer antibody. This antibody was then detected with a secondary antibody conjugated to Alexa Fluor 488 (donor fluorophore). The baseline lifetimes of the donor fluorophore were calculated by single-exponential decay fitting of fluorescence emission in the absence of the acceptor fluorophore. For samples that involved staining for both donor and acceptor, lifetimes were fitted to a bi-exponential decay with lifetime of one component fixed to the donor-only lifetime. Three variables for FLIM were determined: (1) lifetime for the interacting fraction, t 1 , (2) lifetime for the non-interacting fraction, t 2 , and (3) the percentage of interacting molecules, a 1 (%). Because VSVG is transported from the ER to the Golgi, we used this mobility to define key physiological parameters in quantifying the interaction between VSVG and coatomer (based on the t 1 values). The maximal interaction was defined by quantifying VSVG interacting with coatomer at the Golgi, and minimal interaction was defined by performing quantitation when VSVG is at the ER. Interactions of the different forms of VSVG with coatomer were then expressed as the fraction of the maximal interaction (coatomer interacting with wild-type VSVG at the Golgi). COPI reconstitution system. The two-stage incubation system was performed as described previously 9, 14 . In brief, Golgi membrane (250 mg) was washed with 100 ml of 3 M KCl for 5 min, and then diluted with 1 ml of reaction buffer (25 mM HEPES-KOH, pH 7.2, 50 mM KCl, 2.5 mM magnesium acetate, 1 mg ml 21 soybean trypsin inhibitor, 1 mg ml 21 BSA and 200 mM sucrose). In the first stage, the washed membrane was incubated with ARF1, coatomer and GTP at 37 uC for 10 min. Reaction was stopped on the ice water for 5 min, followed by centrifugation at 12,000g for 20 min. In the second stage, the pellet was resuspended with reaction buffer, and then incubated with ARFGAP1 and BARS for 20 min to generate COPI vesicles, or additionally with CDC42 and/or cPLA 2a to generate COPI tubules. Liposome tubulation assay. Liposomes were generated using a mixture of pure lipids (Avanti Polar Lipids): DOPC (33%), DOPS (5%), DOPE (15%), phosphatidic acid (30%) and cholesterol (18%). Lipids (500 mg) in glass tubes were evaporated under nitrogen gas. Lipids were resuspended with assay buffer (25 mM HEPES, pH 7.2, 50 mM KCl, 2.5 mM magnesium acetate and 200 mM sucrose) and hydrated overnight. Liposomes were then passed through 400-nm filter membrane (Whatman) in a mini-extruder (Avanti Polar Lipids). Recombinant CDC42 was then incubated with liposomes at room temperature for 30 min, followed by electron microscopy analysis. Electron microscopy analysis. Electron microscopy analysis of Golgi tubules has been described previously 9 . In brief, membrane samples were loaded on electron microscopy grids and then fixed with 2% paraformaldehyde (PFA) in PBS for 10 min. After blocking with 1% BSA in PBS for 10 min, grids were rinsed with water, followed by uranyl acetate staining. Golgi tubule was detected using JEOL 1200EX transmission electron microscope. To detect cargoes in the reconstituted tubules, immunogold labelling was performed, which involved incubation with mouse anti-Myc antibody (9E10) for 1 h to detect the Myc-tagged form of either VSVG or VSVG-KDELR. After rinsing with PBS, the sample was incubated with a rabbit anti-mouse antibody for 30 min. After an additional rinse
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with PBS, the sample was further incubated with protein A (conjugated with 10 nm gold particles). Grids were then washed with water, followed by uranyl acetate staining, and then examination by electron microscopy. Fifty electron microscopy meshes were examined for quantification in each condition of an experiment. Gel filtration chromatography. Dimerization of CDC42 was determined using Superdex 200 10/300 GL (GE Healthcare), essentially as previously described 18 . Recombinant CDC42 was applied at a flow rate of 0.5 ml min 21 and monitored by ultraviolet detector. 
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